The Efficacy and Safety of Steroids for Preventing Postembolization Syndrome after Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma.
antipyretic
hepatocellular carcinoma
steroid
therapeutic chemoembolization
Journal
Acta medica Okayama
ISSN: 0386-300X
Titre abrégé: Acta Med Okayama
Pays: Japan
ID NLM: 0417611
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
entrez:
24
8
2019
pubmed:
24
8
2019
medline:
7
2
2020
Statut:
ppublish
Résumé
Steroids are often administered at the time of transcatheter arterial chemoembolization (TACE), a standard treatment of hepatocellular carcinoma (HCC), with the expectation of preventing postembolization syndrome. Here we investigated the precise effects of steroids on TACE. We prospectively enrolled 144 HCC patients from 10 hospitals who underwent TACE. Three hospitals used steroids (steroid group, n=77) and the rest did not routinely use steroids (control group, n=67). The occurrence of adverse events and the algetic degree at 1-5 days post-treatment were compared between the groups. Fever (grades 0-2) after TACE was significantly less in the steroid group (56/21/0) compared to the control group (35/29/3, p=0.005, Cochran-Armitage test for trend). The suppressive effect of steroids against fever was prominent in females (p=0.001). Vomiting (G0/G1/ G2-) was also less frequent in the steroid group (70/5/2) versus the control group (53/10/3), but not significantly (p=0.106). The algetic degree and the grade of hematological adverse events, including hyperglycemia, did not differ between the groups. We conclude that the administration of steroids was useful for the prevention of adverse events after TACE in patients with HCC.
Substances chimiques
Steroids
0
Types de publication
Controlled Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
333-339Déclaration de conflit d'intérêts
No potential conflict of interest relevant to this article was reported.
Références
Bruix J, Sherman M and American Association for the Study of Liver D: Management of hepatocellular carcinoma: an update. Hepatology (2011) 53: 1020-1022.
Lencioni R, Petruzzi P and Crocetti L: Chemoembolization of hepatocellular carcinoma. Semin Intervent Radiol (2013) 30: 3-11.
Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Tibballs J, Meyer T, Patch DW and Burroughs AK: Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc intervent Radiol (2007) 30: 6-25.
Horikawa M, Miyayama S, Irie T, Kaji T and Arai Y: Development of Conventional Transarterial Chemoembolization for Hepatocellular Carcinomas in Japan: Historical, Strategic, and Technical Review. AJR Am J Roentgenol (2015) 205: 764-773.
Blackburn H and West S: Management of Postembolization Syndrome Following Hepatic Transarterial Chemoembolization for Primary or Metastatic Liver Cancer. Cancer Nurs (2016) 39: E1-E18.
European Association For The Study Of The L, European Organisation For R and Treatment Of C: EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol (2012) 56: 908-943.
Matsui O, Miyayama S, Sanada J, Kobayashi S, Khoda W, Minami T, Kozaka K and Gabata T: Interventional oncology: new options for interstitial treatments and intravascular approaches: superselective TACE using iodized oil for HCC: rationale, technique and outcome. J Hepatobiliary Pancreat Sci (2010) 17: 407-409.
National Cancer Institute: Common Terminology Criteria for Adverse Events v.4.0 (CTCAE).
Ho CM, Wu HL, Ho ST and Wang JJ: Dexamethasone prevents postoperative nausea and vomiting: benefit versus risk. Acta Anaesthesiol Taiwan (2011) 49: 100-104.
Latreille J, Pater J, Johnston D, Laberge F, Stewart D, Rusthoven J, Hoskins P, Findlay B, McMurtrie E, Yelle L, Williams C, Walde D, Ernst S, Dhaliwal H, Warr D, Shepherd F, Mee D, Nishimura L, Osoba D and Zee B: Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (1998) 16: 1174-1178.
Italian Group for Antiemetic R: Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med (1995) 332: 1-5.
Markman M, Sheidler V, Ettinger DS, Quaskey SA and Mellits ED: Antiemetic efficacy of dexamethasone. Randomized, double- blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy. N Engl J Med (1984) 311: 549-552.
Aapro MS and Alberts DS: Dexamethasone as an antiemetic in patients treated with cisplatin. N Engl J Med (1981) 305: 520.
Pieretti S, Di Giannuario A, Di Giovannandrea R, Marzoli F, Piccaro G, Minosi P and Aloisi AM: Gender differences in pain and its relief. Ann Ist Super Sanita (2016) 52: 184-189.
Kogut MJ, Chewning RH, Harris WP, Hippe DS and Padia SA: Postembolization syndrome after hepatic transarterial chemoembolization: effect of prophylactic steroids on postprocedure medication requirements. Journal of vascular and interventional radiology: JVIR (2013) 24: 326-331.